IN8Bio (formerly known as Innatus Therapeutics, Incysus Therapeutics) is a clinical-stage biopharmaceutical company focused on the development of gamma-delta T cell therapies for the treatment of cancer. It develops the DeltEx platform designed to identify and eradicate tumor cells. The company also researches the INB-100 allogeneic clinical program intended to demonstrate the safety of donor-derived gamma-delta T cells.